The 72 rating InvestorsObserver gives to Zymeworks Inc (ZYME) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 75 percent of stocks in the Biotechnology industry, ZYMEs 72 overall rating means the stock scores better than 72 percent of all stocks.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Zymeworks Inc (ZYME) stock is higher by 1.57% while the S&P 500 is down -1.97% as of 11:26 AM on Monday, Jun 15. ZYME is higher by $0.53 from the previous closing price of $34.15 on volume of 94,857 shares. Over the past year the S&P 500 is higher by 3.17% while ZYME is higher by 68.02%. ZYME lost -$3.88 per share the over the last 12 months.

To screen for more stocks like ZYME click here.

More here:
Is Zymeworks Inc (ZYME) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver